Drug Trial Radar · NCT04512235
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
281
Actual
Start
Nov 3, 2020
Primary completion
Apr 8, 2025
Study completion Apr 8, 2027
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves overall survival, reduces cardiovascular related hospitalizations and it is safe and well tolerated in patients with stage IIIa AL amyloidosis.
Conditions
- AL Amyloidosis
Interventions
CAEL-101Drug
The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.
PlaceboOther
Commercially available 0.9% Normal Saline will be used as the placebo.
cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimenDrug
According to institutional standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- A Hierarchical Combination of Time to All-cause Mortality and Frequency of Cardiovascular Hospitalizations (CVHs) Analyzed by Win RatioTime frame: Day 1 through end of the participant's PETP (Participants were enrolled on a rolling basis. Therefore, the primary analysis for the study was conducted 18-49 months after the study randomization.)
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 through end of the participant's PETP (Participants were enrolled on a rolling basis. Therefore, the primary analysis for the study was conducted 18-49 months after the study randomization.)
Locations
110 sites in 19 countries. Site status is shown where the registry gives one.
Research Site
Scottsdale, Arizona
Research Site
Duarte, California
Research Site
Palo Alto, California
Research Site
San Francisco, California
Research Site
Jacksonville, Florida
Research Site
Weston, Florida
Research Site
Indianapolis, Indiana
Research Site
New Orleans, Louisiana
Research Site
Baltimore, Maryland
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Detroit, Michigan
Research Site
Rochester, Minnesota
Research Site
St Louis, Missouri
Research Site
New York, New York
Research Site
New York, New York
Research Site
Rochester, New York
Research Site
Chapel Hill, North Carolina
Research Site
Durham, North Carolina
Research Site
Winston-Salem, North Carolina
Research Site
Cleveland, Ohio
Research Site
Columbus, Ohio
Research Site
Portland, Oregon
Research Site
Philadelphia, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Dallas, Texas
Research Site
Houston, Texas
Research Site
Salt Lake City, Utah
Research Site
Seattle, Washington
Research Site
Madison, Wisconsin
Research Site
Milwaukee, Wisconsin
Research Site
Box Hill, Australia
Research Site
Murdoch, Australia
Research Site
Westmead, Australia
Research Site
Woolloongabba, Australia
Research Site
Linz, Austria
Research Site
Vienna, Austria
Research Site
Anderlecht, Belgium
Research Site
Leuven, Belgium
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.